Therefore, while our multi-cohort validation strategy strengthens the overall conclusion that MED12 mutation is associated with improved ICI outcomes, the low mutation frequency underscores the need for cautious interpretation of the magnitude of effect within individual studies and highlights the critical need for validation in larger, prospectively collected NSCLC cohorts specifically designed to assess this biomarker. The gene discussed is MED12; the disease is non-small cell lung carcinoma.